Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: A pilot study

Japanese Journal of Cancer Research

Volumn 90, Issue 4, 1999, Pages 367-371

  Tanaka, Katsuaki ^a   Ikeda, Masanori ^a,b   Nozaki, Akito ^a,b   Kato, Nobuyuki ^b   Tsuda, Hiroyuki ^b   Saito, Satoru ^a   Sekihara, Hisahiko ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Chronic hepatitis; Hepatitis C virus; Lactoferrin

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; LACTOFERRIN; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0032962172     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00756.x     Document Type: Article

References (25)

1. Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W. and Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 244, 359-362 (1989).
2. Kuo, G., Choo. Q. L., Alter, H. J., Gitnick, G. L., Redwker, A. G., Purcell, R. H., Miyamura, T., Dienstag, J. L., Alter, M. J., Stevens, C. E., Tegtmeier, G. E., Bonino, F., Colombo, W. S., Lee, W. S., Kuo, C., Berger, K., Shuster, J. R., Overby, L. R., Bradley, D. W. and Houghton, M. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science, 244, 362-364 (1989).
3. Ohkoshi, S., Kojima, H., Tawaraya, H., Miyajima, T., Kamimura, T., Asakura, H., Satoh, A., Hirose, S., Hijikata, M., Kato, N. and Shimotohno, K. Prevalence of antibody against non-A, non-B hepatitis virus in Japanese patients with hepatocellular carcinoma. Jpn. J. Cancer Res., 81, 550-553 (1990).
4. Saito, I., Miyamura, T., Ohbayashi, A., Harada, H., Katayama, T., Kikuchi, S., Watanabe, Y., Koi, S., Onji, M., Ohta, Y., Choo, Q. L., Houghton, M. and Kuo, G. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA, 87, 6547-6549 (1990).
5. Hoofnagle, J. H., Mullen, K. D., Jones, D. B., Rustgi, V., Di Bisceglie, A., Peters, M., Waggoner, J. G., Park, Y. and Jones, E. A. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N. Engl. J. Med., 315, 1575-1578 (1986).
6. Di Bisceglie, A. M., Martin, P., Kassianides, C., Lisker-Melman, M., Murray, L., Waggoner, J., Goodman, Z., Banks, S. M. and Hoofnagle, J. H. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N. Engl. J. Med., 321, 1506-1510 (1989).
7. Tine, F., Margin, S., Craxi, A. and Pagliaro, L. Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomized clinical trials. J. Hepatol., 13, 192-199 (1991).
8. Marcellin, P., Boyer, N., Giostra, E., Degott, C., Courouce, A. M., Degos, F., Coppere, H., Cales, P., Couzigou, P. and Benhamou, J.-P. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology, 13, 393-397 (1991).
9. Shiratori, Y., Kato, N., Yokosuka, O., Imazeki, F., Hashimoto, E., Hayashi, N., Nakamura, A., Asada, M., Kuroda, H., Tanaka, N., Arakawa, Y. and Omata, M. for the Tokyo-Chiba Hepatitis Research Group. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology, 113, 558-566 (1997).
10. Kato, N., Ikeda, M., Mizutani, T., Sugiyama, K., Noguchi, M., Hirohashi, S. and Shimotohno, K. Replication of hepatitis C virus in cultured non-neoplastic human hepatocytes. Jpn. J. Cancer Res., 87, 787-792 (1996).
11. Ikeda, M., Kato, N., Mizutani, T., Sugiyama, K., Tanaka, K. and Shimotohno, K. Analysis of cell tropism of HCV by using in vitro HCV-infected human lymphocytes and hepatocytes. J. Hepatol., 27, 445-454 (1997).
12. Ikeda, M., Sugiyama, K., Mizutani, T., Tanaka, T., Tanaka, K., Sekihara, H., Shimotohno, K. and Kato, N. Human hepatocyte clonal cell lines that support persistent replication of hepatitis C virus. Virus Res., 56, 157-167 (1998).
13. Hasegawa, K., Motsuchi, W., Tanaka, S. and Dosako, S. Inhibition with lactoferrin of in vitro infection with human herpes virus. Jpn. J. Med. Sci. Biol., 47, 73-85 (1994).
14. Kirkpatrick, C. H., Green, I., Rich, R. R. and Schade, A. L. Inhibition of growth of Candida albicans by iron-unsaturated lactoferrin: relation to host-defense mechanisms in chronic mucocutaneous candidiasis. J. Infect. Dis., 124, 539-544 (1971).
15. Yamanouchi, K., Tomita, M., Giehl, T. J. and Elison, R. T., III. Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect. Immun., 61, 719-728 (1993).
16. Harmsen, M. C., Swart, P. J., De Bethune, M.-P., Pauwels, R., De Clercq, E., The, T. H. and Meijer, D. K. F. Antiviral effects of plasma milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J. Infect. Dis., 172, 380-388 (1995).
17. Superti, F., Ammendolia, M. G., Valent, P. and Seganti, L. Antirotaviral activity of milk protein: lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT-29. Med. Microbiol. Immunol. (Berl.), 186, 83-91 (1997).
18. Ikeda, M., Sugiyama, K., Tanaka, T., Tanaka, K., Sekihara, H., Shimotohno, K. and Kato, N. Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem. Biophys. Res. Commun., 245, 549-553 (1998).
19. Brock, J. Lactoferrin: a multifunctional immunoregulatory protein? Immunol. Today, 16, 417-419 (1995).
20. Levay, P. F. and Viljoen, M. Lactoferrin: a general review. Haematologica, 80, 252-267 (1995).
21. Yi, M., Kaneko, S., Yu, D. Y. and Murakami, S. Hepatitis C virus envelope proteins bind lactoferrin. J. Virol., 71, 5997-6002 (1997).
22. Hagiwara, H., Hayashi, N., Mita, E., Takehara, T., Kasahara, A., Fusamoto, H. and Kamada, T. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy. Gastroenterology, 104, 877-883 (1993).
23. Gil, B., Quian, C., Riezu-Boj, J. I., Civeira, M. P. and Prieto, J. Hepatic and extrahepatic HCV RNA strands in chronic hepatitis C: different patterns of response to IFN treatment. Hepatology, 18, 1050-1054 (1993).
24. Sekine, K., Watanabe, E., Nakamura, J., Takasuka, N., Kim, D. J., Asamoto, M., Krutovskikh, V., Baba-Toriyama, H., Ota, T., Moore, M. A., Masuda, M., Sugimoto, H., Nishino, H., Kakizoe, T. and Tsuda, H. Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats. Jpn. J. Cancer Res., 88, 523-526 (1997).
25. Hutchens, T. W., Henry, J. F. and Yip, T.-T. Structurally intact (78-kDa) forms of maternal lactoferrin purified from urine of preterm infants fed human milk: identification of a trypsin-like proteolytic cleavage event in vivo that does not result in fragment dissociation. Proc. Natl. Acad. Sci. USA, 88, 2994-2998 (1991).